CAR-T Therapy

In a recent breakthrough for cancer treatment, a team of researchers has developed HSP-CAR30, a novel CAR-T cell therapy that has shown remarkable efficacy in treating relapsed or refractory CD30-positive lymphomas—diseases notoriously resistant to conventional therapies.

Key Features of the Innovation

  • Targets the CD30 protein, commonly found in Hodgkin lymphoma and CD30-positive T-cell lymphomas.
  • Demonstrated 100% overall response rate in Phase I clinical trials—an extraordinary result for heavily pre-treated patients.
  • Achieved 50% complete remission, with disease becoming undetectable through imaging and clinical evaluation.

What is CAR T Cell Therapy?

  • CAR (Chimeric Antigen Receptor) T cell therapy ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Science & Technology